Dendreon Corporation to Speak at Needham & Company Biotechnology Conference and BIO 2002 Meeting.Business Editors/Health & Medical Writers BIOWIRE2K BIO 2002 SEATTLE--(BW HealthWire)--May 31, 2002 Dendreon Corporation (Nasdaq:DNDN) today announced that it will present at the First Annual Needham & Company Biotechnology Conference on June 4, 2002 at the Millennium Broadway Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. and at the Investor Forum of the BIO 2002 International Biotechnology Conference & Exhibition taking place June 9-12, 2002 in Toronto. Martin Simonetti, senior vice president of finance and chief financial officer, will be presenting at the Needham Conference on June 4 at 2:30 p.m., EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT . His presentation will be webcast live at www.needhamco.com and on Dendreon's website www.dendreon.com under the "News & Events" section. The webcast will also be archived for future on-demand replay. Mitchell H. Gold, M.D., the company's chief business officer, will present at the BIO 2002 Investor Forum at the Metro Toronto Convention Centre Metro Toronto Convention Centre, located in Downtown Toronto, Ontario at 255 Front Street West, has 600,000 square feet of space. The convention centre was completed in October 1984 and is home to the 1330 seat John Bassett Theatre, currently used for Canadian Idol. on June 12 at 11:00 a.m., EDT. The presentation will be webcast live and available on Dendreon's website www.dendreon.com under the "News & Events" section. The webcast will also be archived for future on-demand replay. Dendreon Corporation (www.dendreon.com) is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. . Dendreon currently has three therapeutic vaccines in clinical trials: Provenge(TM) in Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trials for prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. , Mylovenge(TM) in Phase II trials for multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility and APC (1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. 8024 in Phase I trials for breast, ovarian and colon cancers. Dendreon's product pipeline includes monoclonal antibodies and a pathway to small molecules. For more information, visit www.dendreon.com. Except for historical information contained herein, this news release contains forward looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to Dendreon's limited operating history, the risk of loss of key employees, risks associated with the completing or failing to complete clinical trials, the risk that the safety and/or efficacy results of a clinical trial, including those of our completed phase III trial for Provenge, will not support an application for a biologics license, the risk the company may not satisfy regulatory requirements or that the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. will not be satisfied with the data we provide for Provenge or approve a product for which a biologics license has been applied, the uncertainty of Dendreon's future access to capital, the failure by Dendreon to secure and maintain relationships with collaborators, dependence on the efforts of third parties, and dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's public disclosure filings with the US. Securities and Exchange Commission, including the Company's annual report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2001, which are available at www.sec.gov. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion